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T he involvement of the renin-angiotensin system (RAS) in the occurrence of atherosclerotic plaque instabilisation has already been addressed. An increased accumulation of angiotensin-converting enzyme (ACE), of angiotensin II, and of angiotensin II type 1 (AT 1 ) receptors has been demonstrated in human coronary arteries in the course of acute coronary syndromes, in relationship with the amount of activated macrophages present in the atherosclerotic plaque. [1] [2] [3] RAS activity in stable atherosclerotic lesions is still under investigation. [4] [5] [6] Despite the diffuse utilisation of stents, restenosis after percutaneous coronary interventions (PCI) still develops in 10-21% after stent placement. 7 Histopathological differences suggest a different pathogenesis for in-stent restenotic and atherosclerotic de-novo lesions. In de-novo coronary atherosclerosis, the angiotensin-converting enzyme (ACE) has emerged as one of the factors involved in the process of lesion formation, since an increased accumulation of ACE in humans has been demonstrated in atherosclerotic coronary and carotid arteries. [4] [5] [6] In-stent restenosis seems to be caused exclusively by neointimal proliferation. 8 In-stent restenotic lesions contain mainly smooth muscle cells and show more active proliferation of smooth muscle cells than native lesions and even restenotic lesions after balloon angioplasty. 9 Given the fact that smooth muscle cell proliferation can be induced by angiotensin II via the AT 1 receptor under experimental conditions, [10] [11] [12] we investigated the potential involvement of the renin-angiotensin system in the development of human in-stent restenosis. For this purpose we used atherectomy specimens retrieved from patients with in-stent restenotic lesions, in which the immunoreactivity of smooth muscle cells and inflammatory cells with anti-ACE and anti-AT 1 receptor antibodies were evaluated. Moreover, the results were compared with atherectomies from de-novo atherosclerotic lesions subjected to similar immunohistochemical procedures.
METHODS

Study population
Consecutive patients with recurrent stable angina or inducible ischemia after coronary stenting, and the angiographic finding of in-stent restenosis were enrolled (n=19). In-stent restenosis was defined as an in-stent lumen diameter of less than 50% of the vessel. A second population of symptomatic patients with significant de-novo coronary lesions, matched for age, gender and lesion location was also selected (n=19). These patients had stable angina and type B2 or C lesions in the proximal left anterior descending artery or the ramus circumflex. Exclusion criteria for both groups were unstable angina and/or non-Q wave myocardial infarction, total coronary occlusion, vessel reference diameter <3.0 mm, excessive tortuosity of the proximal vessel and the use of an ACE-inhibitor or an angiotensin II type 1 receptor blocker. 
Tissue collection
Percutaneous coronary atherectomy was performed, both in de-novo lesions and in in-stent restenosis, by means of a pullback atherectomy catheter (Arrow int., Reading, PA, USA). Briefly, this 10-french compatible over-the-wire catheter is positioned beyond the lesion to treat. After the cutting blade is exposed and on-axis high-speed rotation is started, the catheter is gently withdrawn by manual pullback. This procedure allows complete circumferential cuts along the whole length of the lesion, thus providing in vivo plaque samples, suitable for histopathological analysis. In all patients, one biopsy was taken out of the culprit lesion. Coronary angiography before and after the atherectomy confirmed that the sample was taken from the lesion. After collection, the samples were immediately frozen in liquid nitrogen and stored in a -80 °C freezer.
Tissue preparation and staining techniques
Frozen specimens were oriented along their longest axis in Tissue Tek. Of each specimen, 5 µm sections serially cut were mounted in duplo on glass slides. One slide was stained with Haematoxylin & Eosin staining and consecutive serial sections were used for immuno-histochemistry. The primary antibodies we used were reactive with epitopes specific for macrophages (CD68 (clone EBM11), DAKO, Glostrup, Denmark), α-smooth muscle cells (SMA-1 (clone 1A4), DAKO, Glostrup, Denmark), ACE (mouse antibody (clone 9B9), Chemicon, Temecula, CA, USA) and the AT 1 receptor (rabbit antibody, Biotrend, Köln, Germany). Acetone fixed sections were subjected to a three-step streptavidin-biotin alkaline phosphatase (AP) staining procedure. ACE and AT 1 receptor antibodies were incubated overnight at 4°C. Tris-buffered saline was used for washing between the subsequent incubation steps. Biotinylated goat anti-mouse immunoglobulin (1:200) or biotinylated goat anti-rabbit immunoglobulin (1:400)(both DAKO, Glostrup, Denmark) were used as second step (30 minutes room temperature), AP-conjugated streptavidin (DAKO) as third step (1:100; 30 minutes room temperature). AP enzymatic activity was visualised using the Fast Red tablet substrate system (DAKO).
Immuno doublestaining for the simultaneous identification of smooth muscle cells and macrophages was based on two primary antibodies of different IgG subclasses as described earlier. 13 Using AP as enzymatic marker macrophages were visualised in blue with Fast Blue BB/Naphthol-AS-MX-phosphate as chromogens (Sigma, ST Louis, MO, USA). Smooth muscle cells were developed in red with peroxidase as marker enzyme and 3-amino-9-ethylcarbazole (Sigma) as chromogen. Sections of alveolar lung tissue and infarcted myocardium served as positive controls for anti-ACE and anti-AT 1 staining.
Analysis of immunostaining
A semi-quantitative score of ACE, AT 1 receptor, CD68 and SMA-1 staining was applied by two independent persons (AvdW, LJW) in order to evaluate the cell type and number of cells positive in each biopsy. These persons were blinded to the patient characteristics. The weighted kappa for interobserver variability was 0.65. The semi-quantitative score we used is as follows: 0: absent; 1: few scattered cells or clusters <5 cells; 2: <10% of cells positive; 3: 10-50% of cells positive; 4: >50% of cells positive. An immunodouble stain for smooth muscle cells and macrophages was used to facilitate the semi-quantitative scoring of macrophages and smooth muscle cells in each biopsy, and to establish the immunolocalisation of ACE and the AT 1 receptor in different cell types. Anti-ACE and anti-AT 1 stains were not useful for doublestaining procedures in combination with cell-specific stains (CD68 and SMA-1) because of huge differences in staining intensity.
Statistical analysis
Two-tailed T-test and Chi-square tests were performed to compare continuous and categorical variables, respectively. A Spearman correlation (SPSS for Windows 10.1) was used to compare the influence of timing of the biopsy on the histological parameters. A weighted kappa coefficient (SPSS for Windows 10.1) was calculated to determine the interobserver agreement. Differences were considered significant at a level of P<0.05.
RESULTS
Patient groups were generally well matched with respect to their baseline characteristics, although hyperlipidemia was more frequent in patients with in-stent restenosis. Neither the presence of hyperlipidemia, nor the cholesterol level did relate to the immunohistochemical outcome parameters of this study (data not shown). In biopsies from de-novo stenoses a combination of different tissue components was found, including sclerotic tissue and lipid cores. Thrombus was found in only one biopsy. In 3 specimens (16%), neointimal formation was found. All but one biopsies contained both macrophages (CD68-positive) and smooth muscle cells (SMA-1-positive), but in highly variable amounts. One biopsy contained only smooth muscle cells without CD-68-positive cells. Only three biopsies contained vascular smooth muscle cells (VSMCs), consistent with neointimal proliferation, i.e. stellate shaped smooth muscle cells embedded in abundant myxoid extracellular matrix. Anti-ACE staining was observed in macrophages only. Smooth muscle cells were always ACE-negative. Anti-AT 1 receptor staining was seen on both macrophages and smooth muscle cells, but macrophages showed higher staining intensity. Typical examples of biopsies from de-novo stenoses are shown in figure 1a-c. In-stent restenotic lesions contained predominantly stellate shaped VSMCs in abundant myxoid matrix, characteristic for neointimal tissue. Macrophages were either absent (11% of the tissue specimens) or present in small clusters (89%). Also in in-stent restenosis, anti-ACE staining was only seen in the macrophages, if present, whereas macrophages and all smooth muscle cells, including the stellate VSMCs in the neointimal tissue, were AT 1 receptor-positive. Typical examples of biopsies from in-stent restenoses are shown in figure 2a-c. Semi-quantitative analysis of immunostaining showed that in-stent restenotic lesions contained more VSMCs (p=0.003), but less macrophages (p=0.002), than de-novo lesions (Figure 3) . Moreover, in-stent restenotic lesions showed less ACE-positive cells (p=0.02), but slightly more AT 1 receptor staining, allthough not significant (p=0.16), when compared with de-novo lesions (Figure 3) . Therefore, the overall expression of AT 1 receptors in restenotic lesions appeared much more abundant than in de-novo lesions with similar clinical presentation. The time between the stent placement and the biopsy in patients with in-stent restenosis appeared to be negatively correlated with the amount of macrophages in the in-stent restenotic plaque (r=-0.558; p=0.013), although the number of cases in this instance is very small (Figure 4 ). As ACE was only seen in macrophages, the timing of the biopsy is also negatively correlated to the ACE-content in the plaque (r=-0.571; p=0.011). 
. Immunodouble stain with anti-CD68 (blue) and anti-SMA-1 (red brown) antibodies showing a bandlike infiltrate of anti-CD68 positve macrophages (blue) in the upper part of the tissue (area above two arrows) and large amounts of vascular anti-SMA-1 positive smooth muscle cells (red brown) in
. Immunodouble stain with anti-CD68 antibody (blue, macrophages) and anti-SMA-1 antibody (red, smooth muscle cells). The tissue composition is dominated by large amounts of spindle shaped smooth muscle cells (red). In between is a cluster of macrophages
DISCUSSION
This study demonstrates the potential involvement of the renin-angiotensin system in the development of in-stent restenosis in human coronary arteries. Moreover, different patterns evolve comparing in-stent restenosis with de-novo stable coronary lesions. In de-novo stenosis, ACE was present in macrophage-rich regions in all specimens. The AT 1 receptor was found on vascular smooth muscle cells (VSMCs) and macrophages. In in-stent restenosis, ACE-staining was limited to the macrophages, if present, and hence in much lower quantities than in de-novo lesions. The AT 1 receptor on the other hand was more abundantly present in in-stent restenotic lesions, especially due to the large number of VSMCs.
Atherosclerosis and the renin-angiotensin system
Recent observations suggested that RAS might be involved in the occurrence of acute coronary syndromes. In fact, co-localisation of elevated ACE and angiotensin II, the RAS effector molecule in the vessel wall, in macrophages-rich areas of atherosclerotic plaques has already been demonstrated. 1, 2 It is well-known that activated macrophages play a major role in plaque inflammation and subsequent disruption. 3 Moreover, several studies have shown the effectiveness of ACE-inhibitors in reducing the incidence of cardiovascular adverse events.
14,15 Although Powell et al. showed reduction of restenosis by ACE inhibitors in a rat model of balloon angioplasty, 16 chronic ACE inhibition did not prevent restenosis after non-stent PTCA in humans. 17, 18 In our study, ACE immunoreactivity appeared mainly as distinct granules in the cytoplasm of inflammatory cells and was present in all biopsies of de-novo lesions. The pathophysiological effects of angiotensin II, the effector molecule of the reninangiotensin system, in the vessel wall are mediated through the AT 1 receptor. 10, 12, [19] [20] [21] Blockade of the AT 1 receptor, as well as ACE-inhibition, could be helpful in premature atherosclerosis, as already proven in animal models and humans. 22, 23 We found the AT 1 receptor to be present on both macrophages and VSMCs in the atherosclerotic plaque.
In-stent restenosis and the renin-angiotensin system
The process of in-stent restenosis has been described in several post-mortem studies. 9, [24] [25] [26] The first step in the process is platelet deposition and aggegration, which is followed by a period of thrombus formation and inflammation, mainly at the sites of the struts. Smooth muscle cells are detected from 9-12 days after stent placement. After circa 30 days, neither thrombi nor acute inflammatory cells are found. At that time, chronic inflammation is still detectable around the struts, but the newly formed tissue responsible for restenosis development mainly consists of smooth muscle cells (96% of total plaque area) embedded in a proteoglycan rich matrix. Such a tissue composition is characteristic for neointima formation. Activation of the renin-angiotensin system is one of the possible mechanisms for VSMCproliferation. Angiotensin II is able to induce proliferation of VSMCs, a key mechanism in in-stent restenosis, via stimulation of AT 1 receptors in experimental models. [10] [11] [12] 27, 28 However, apart from a case report, 29 which showed ACE-activity in restenotic material from a popliteal stent, RAS contribution to human in-stent restenosis has not been elucidated yet. In our biopsies, the immunoreactivity with anti-ACE was restricted to inflammatory cells, and present in 74% of in-stent restenotic lesions. A higher amount of macrophages (and hence of ACE-staining) was found in in-stent restenotic lesions that had the shortest interval between the stent placement and the biopsy. This indicates that also in in-stent restenosis infiltration of inflammatory cells may play a role in the RAS-pathway. The fact that we still found macrophage-rich lesions more than 30 days after stent placement is in contradiction with the above-mentioned studies about the genesis of in-stent restenosis. The presence of the AT 1 receptor on the abundantly present VSMCs in this tissue might indicate that the RAS plays a role in the growth and migration of VSMCs in in-stent restenosis. However, the role of ACE in the genesis of in-stent restenosis is still unclear. Several studies reported that the ACE-inhibitor quinapril reduces in-stent intimal hyperplasia, late luminal loss and restenosis rate. [30] [31] [32] Also, a recent retrospective study in 1598 patients suggested that ACE-inhibitors decrease late revascularisation after stent placement. 33 In the PARIS study, on the other hand, quinapril was not able to prevent in-stent restenosis in patients with the DD genotype of ACE. 34 It remains controversial whether patients with the DD-allele of the ACE-polymorphism are especially at risk for in-stent restenosis, due to their higher ACE-activity. The D-allele has been identified as a prognostic factor for instent restenosis in some studies, 35, 36 but other larger studies did not confirm this. [37] [38] [39] Since the effects of the RAS are mediated via the AT 1 receptor, blockade of the AT 1 receptor could be expected to be effective in preventing in-stent restenosis. The results of the present study may endorse the outcome of a recently published study in 250 patients, which demonstrates the effectiveness of the AT 1 receptor blocker valsartan in preventing in-stent restenosis after angioplasty with stent placement in type B2/C lesions. 40 Larger studies will be necessary to confirm this hypothesis.
CONCLUSIONS
Our results are consistent with involvement of the renin-angiotenin system in stable coronary atherosclerosis. In de-novo lesions ACE and AT 1 receptors were found on macrophages, which were present in all specimens. All VSMCs were AT 1 -positive, but less intense than the macrophages. In contrast, in-stent restenotic lesions consisted mainly of AT 1 receptorpositive VSMCs, highly characteristic for neointimal proliferation. Macrophages were present in most biopsies, but only in small amounts. Anti-ACE and anti-AT 1 receptor staining was seen on most of these macrophages. This might demonstrate the important role of the renin-angiotensin system, and especially the AT 1 receptor in in-stent restenosis.
